Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

Bristol Myers Squibb (BMS) has shared promising results from a late-stage study of its dual immunotherapy combination in ...

An immunotherapy combination for advanced, highly mutated colorectal cancer (CRC) significantly slowed disease progression ...

Metastatic colorectal cancer with microsatellite instability-high or mismatch repair-deficient status represents a distinct ...

Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...

Dr. Guglietta: Yes. So, it's exactly the challenge. And what we are actually seeing is that at the moment, especially for ...

Researchers have shown that the amount of a protein called CD74 can indicate which people with bowel cancer may respond best to immunotherapy.

Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme—P4HA1 prolyl hydroxylase, ...

This mini-review highlights the latest advancements in tumor immunotherapy, with a focus on cellular therapies, and addresses the resistance mechanisms that hinder their effectiveness in lung and ...

Cancer immunotherapy drugs, which boost the immune system to fight the tumor, have revolutionized the treatment of the deficient subtype of colorectal cancer. However, these drugs only work in about ...

Cancer immunotherapy drugs, which boost the immune system to fight the tumour, have revolutionised the treatment of the deficient subtype of colorectal cancer. However, these drugs only work in ...